RxDoctor Payments Data

John Won, MD

Urology · Flushing, NYNPI 1477630440

Payments from drug & device makers

$8,982in general payments, 2019–2025

Across 181 payments — averaging $49.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$4K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$973
  • Johnson & Johnson$508
  • Teleflex LLC$369
  • Pfizer$356
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$4,08045%
  • Education$7378%
  • Other$4,16446%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,982 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$105,590
Medicare patients
284
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide51$746,907
Lupron DepotLeuprolide Acetate94$499,677
GemtesaVibegron581$435,134
ErleadaApalutamide12$165,985
MyrbetriqMirabegron204$124,900
OrgovyxRelugolix40$108,208
Tamsulosin Hcl3,018$27,031
Finasteride1,828$12,650
Bcg (Tice Strain)Bcg Live16$8,777
Alfuzosin Hcl ErAlfuzosin Hcl442$7,252
Oxybutynin Chloride ErOxybutynin Chloride346$4,571
Dutasteride234$4,337
Silodosin49$4,325
Solifenacin Succinate63$2,287
Tolterodine Tartrate ErTolterodine Tartrate13$839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,017$871,808255 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$973$543,342621 claims
Johnson & JohnsonErleada$508$165,98512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →